Current Urology Reports最新文献_第2页

Strategies to Improve Clinical Outcomes and Patient Experience Undergoing Transurethral Resection of Bladder Tumor. 改善经尿道膀胱肿瘤切除术临床效果和患者体验的策略。

IF 2.5 2区医学

Current Urology Reports Pub Date : 2024-10-11 DOI: 10.1007/s11934-024-01243-3

Sadra Sepehri, Michael E Rezaee, Zhuo Tony Su, Max Kates

{"title":"Strategies to Improve Clinical Outcomes and Patient Experience Undergoing Transurethral Resection of Bladder Tumor.","authors":"Sadra Sepehri, Michael E Rezaee, Zhuo Tony Su, Max Kates","doi":"10.1007/s11934-024-01243-3","DOIUrl":"https://doi.org/10.1007/s11934-024-01243-3","url":null,"abstract":"Purpose of review: To describe patient experiences of transurethral resection of bladder tumor (TURBT) and review recent advances in enhancing clinical outcomes.Recent findings: High rates of recurrence and progression of non-muscle invasive bladder tumors expose patients to multiple TURBT procedures throughout their disease process. Understanding the impact of TURBT on quality of life and patient experiences is crucial for shared decision-making, thus enhanced recovery protocol trials are being explored to improve patient outcomes. The variability in TURBT practices worldwide contributes to differing bladder tumor recurrence rates, prompting efforts to standardize practices by evaluating the impact of patient, hospital, and surgeon factors. For select cases, less intensive surveillance regimens have reduced toxicities and costs without compromising oncologic outcomes. New innovative approaches such as en bloc- and stratified resection techniques may reduce perioperative complications and improve clinical outcomes. Finally, neoadjuvant and ablative treatments have shown to be promising alternatives to TURBT, necessitating further investigation in this setting. TURBT is essential for diagnosing and treating bladder cancer. Reducing associated morbidities and improving surgical outcomes involve multifaceted approaches, including standardizing surgical practices, exploring innovative techniques, and optimizing surveillance regimens, all while promoting patient quality of life. Neoadjuvant therapies as alternative treatments are on the horizon and may ultimately change the landscape of bladder cancer care.","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder Cancer. DNA 修复缺陷在不断变化的膀胱癌治疗中的影响。

IF 2.5 2区医学

Current Urology Reports Pub Date : 2024-10-09 DOI: 10.1007/s11934-024-01242-4

Vincent D D'Andrea, Christopher J Magnani, John Ernandez, Joaquim Bellmunt, Matthew Mossanen, Timothy N Clinton, Filipe L F Carvalho, Kent W Mouw

{"title":"Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder Cancer.","authors":"Vincent D D'Andrea, Christopher J Magnani, John Ernandez, Joaquim Bellmunt, Matthew Mossanen, Timothy N Clinton, Filipe L F Carvalho, Kent W Mouw","doi":"10.1007/s11934-024-01242-4","DOIUrl":"https://doi.org/10.1007/s11934-024-01242-4","url":null,"abstract":"Purpose of review: This review explores the current landscape of treatments which target the DNA damage response (DDR) in metastatic and muscle-invasive bladder cancer. It emphasizes recent clinical trials which integrate DDR inhibitors with standard chemotherapy and immunotherapy.Recent findings: Noteworthy findings include the ATLANTIS trial, which demonstrated prolonged progression-free survival (PFS) in DDR biomarker-selected patients using PARP inhibitors as maintenance after standard chemotherapy. Trials such as BAYOU, which combined immunotherapy with PARP inhibition, similarly suggested a potential therapeutic benefit in DDR biomarker-selected patients with bladder cancer. Efforts to develop bladder-sparing treatment regimens based on DDR-associated mutational profiles, such as the RETAIN and HCRN 16-257 trials, have had mixed outcomes to date. There are now ongoing efforts to combine DDR inhibitors with the newest bladder cancer therapies, such as antibody-drug conjugates. This review highlights the most recent advances in targeting DNA repair deficiency in the evolving treatment landscape of bladder cancer.","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Implications of the Molecular and Genomic Landscape of Upper Tract Urothelial Carcinoma. 上尿路上皮癌的分子和基因组图谱对临床的影响

IF 2.5 2区医学

Current Urology Reports Pub Date : 2024-10-08 DOI: 10.1007/s11934-024-01245-1

Salvador Jaime-Casas, Abhishek Tripathi, Sumanta K Pal, Wesley Yip

引用次数: 0

Rapid Lifestyle Recommendations to Improve Urologic, Heart and Overall Health. 改善泌尿系统、心脏和整体健康的快速生活方式建议。

IF 2.5 2区医学

Current Urology Reports Pub Date : 2024-10-08 DOI: 10.1007/s11934-024-01246-0

Mark A Moyad

{"title":"Rapid Lifestyle Recommendations to Improve Urologic, Heart and Overall Health.","authors":"Mark A Moyad","doi":"10.1007/s11934-024-01246-0","DOIUrl":"https://doi.org/10.1007/s11934-024-01246-0","url":null,"abstract":"Purpose of review: This literature review is intended to highlight recent correlations between urologic, heart and overall health by emphasizing healthy eating patterns, physical activity, alcohol minimization and tobacco elimination, healthy sleep, weight, cholesterol, blood sugar, blood pressure management, and mental health awareness.Recent findings: Meta-analyses, systematic reviews, and clinical studies espouse a unified message for prevention, reducing the risk of disease recurrence, progression, complementing conventional medical intervention efficacy, and mitigating treatment side effects. Limiting or eliminating alcohol consumption could be considered an independent recommendation and adding a mental health and miscellaneous (genetic risk and lifestyle, planetary health, HPV or other vaccination awareness, spirituality, etc.) category could allow for individualized educational opportunities, synergism appreciation, and self-improvement. Urologic healthcare professionals have the potential to strengthen the collective public health goal of improving the quality and quantity of the lives of patients able to adhere to these heart healthy recommendations.","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent Advancements in Prostate Catheters and Stents for Management of Benign Prostatic Hyperplasia. 用于治疗良性前列腺增生症的前列腺导管和支架的最新进展。

IF 2.5 2区医学

Current Urology Reports Pub Date : 2024-10-07 DOI: 10.1007/s11934-024-01235-3

John Lama, Joshua Winograd, Alia Codelia-Anjum, Naeem Bhojani, Dean Elterman, Kevin C Zorn, Bilal Chughtai

{"title":"Recent Advancements in Prostate Catheters and Stents for Management of Benign Prostatic Hyperplasia.","authors":"John Lama, Joshua Winograd, Alia Codelia-Anjum, Naeem Bhojani, Dean Elterman, Kevin C Zorn, Bilal Chughtai","doi":"10.1007/s11934-024-01235-3","DOIUrl":"https://doi.org/10.1007/s11934-024-01235-3","url":null,"abstract":"Purpose of review: The prevalence of benign prostatic hyperplasia (BPH) is rising, however, current treatment options present severe complications and limit patient's quality of life. Accordingly, advancements in prostatic catheter and stent designs for use in treating lower urinary tract symptoms (LUTS) in BPH patients have largely expanded in the past five years and we aim to provide an exhaustive summary of recent outcomes.Recent findings: The dual dilation and paxlitaxel eluting Optilume BPH Catheter System enhances promise in catheter-based treatments, providing the longest sustained increase in max urinary flow rate and decrease in post-void residual volume compared to alternative MISTs. Additionally, use of iTiND, along with recent advancements in temporary (EXIME, Prodeon Urocross) and permanent (Zenflow Spring, Butterfly, and ClearRing) stent designs, have demonstrated rapid, lasting, and low-cost LUTS relief with sustained sexual function. Minimally invasive solutions that offer in-office treatment, rapid symptom relief, shorter recovery times, and preservation of sexual function hold great promise in improving outcomes in managing BPH patients with LUTS.","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implementation and Utility of the Da Vinci SP (Single Port) in Pediatric Urology. 达芬奇 SP（单孔）在小儿泌尿外科中的应用和效用。

IF 2.5 2区医学

Current Urology Reports Pub Date : 2024-10-03 DOI: 10.1007/s11934-024-01231-7

Lucas A Arney, Randall G Bissette, Jordan M Smith, Christopher E Bayne

{"title":"Implementation and Utility of the Da Vinci SP (Single Port) in Pediatric Urology.","authors":"Lucas A Arney, Randall G Bissette, Jordan M Smith, Christopher E Bayne","doi":"10.1007/s11934-024-01231-7","DOIUrl":"10.1007/s11934-024-01231-7","url":null,"abstract":"Purpose of review: Detail the evolution, utility, and future directions of the da Vinci SP® in pediatric urology, focusing on perioperative outcomes and intraoperative details.Recent findings: The SP has been safely and successfully utilized in various pediatric urological procedures, from pyeloplasty to nephroureterectomy to appendicovesicostomy. Reports indicate mixed operative times but similar hospital stays and postoperative outcomes compared to multiport (MP) robotic surgery. The learning curve for transitioning from MP to SP systems in pediatric patients appears manageable, though the smaller abdominal circumference in children poses a notable challenge. This review assumes that SP systems will primarily be acquired for adult services, not considering initial and ongoing costs to hospital systems. The SP serves as a complementary option, rather than a replacement, for MP robotic surgery in pediatric urology, offering potential advantages in specific scenarios. Cosmetic outcomes with the SP appear at least as favorable as MP surgery, but further research is needed. Future research should focus on patient-centered outcomes to optimize SP robotic surgery use in pediatric patients.","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial Intelligence Modeling and Priapism. 人工智能建模与 Priapism。

IF 2.5 2区医学

Current Urology Reports Pub Date : 2024-10-01 Epub Date: 2024-06-18 DOI: 10.1007/s11934-024-01221-9

Edoardo Pozzi, David A Velasquez, Alexandra Aponte Varnum, Bruce R Kava, Ranjith Ramasamy

{"title":"Artificial Intelligence Modeling and Priapism.","authors":"Edoardo Pozzi, David A Velasquez, Alexandra Aponte Varnum, Bruce R Kava, Ranjith Ramasamy","doi":"10.1007/s11934-024-01221-9","DOIUrl":"10.1007/s11934-024-01221-9","url":null,"abstract":"Purpose of review: This narrative review aims to outline the current available evidence, challenges, and future perspectives of Artificial Intelligence (AI) in the diagnosis and management of priapism, a condition marked by prolonged and often painful erections that presents unique diagnostic and therapeutic challenges.Recent findings: Recent advancements in AI offer promising solutions to face the challenges in diagnosing and treating priapism. AI models have demonstrated the potential to predict the need for surgical intervention and improve diagnostic accuracy. The integration of AI models into medical decision-making for priapism can also predict long-term consequences. AI is currently being implemented in urology to enhance diagnostics and treatment work-up for various conditions, including priapism. Traditional diagnostic approaches rely heavily on assessments based on history, leading to potential delays in treatment with possible long-term sequelae. To date, the role of AI in the management of priapism is understudied, yet to achieve dependable and effective models that can reliably assist physicians in making decisions regarding both diagnostic and treatment strategies.","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy. 前列腺活检过程中出现疼痛和不适的风险因素和现代处理方案。

IF 2.5 2区医学

Current Urology Reports Pub Date : 2024-10-01 Epub Date: 2024-06-19 DOI: 10.1007/s11934-024-01220-w

Gabriela M Diaz, Lindsey T Webb, Maximilian J Rabil, Soum D Lokeshwar, Ankur U Choksi, Michael S Leapman, Preston C Sprenkle

{"title":"Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy.","authors":"Gabriela M Diaz, Lindsey T Webb, Maximilian J Rabil, Soum D Lokeshwar, Ankur U Choksi, Michael S Leapman, Preston C Sprenkle","doi":"10.1007/s11934-024-01220-w","DOIUrl":"10.1007/s11934-024-01220-w","url":null,"abstract":"Purpose of review: Prostate fusion biopsy, an innovative imaging modality for diagnosing prostate cancer, presents certain challenges for patients including discomfort and emotional distress, leading to nonadherence to treatment and follow-ups. To inform clinicians and offer pain relief alternatives to patients, this review delves into the risk factors for increased pain and modern management options to alleviate pain during prostate biopsy.Recent findings: Individual responses to pain vary, and the overall experience of pain during a prostate biopsy has been contributed to numerous factors such as patient age, prostate volume, previous biopsy experience, and more. As a result, several strategies aim to mitigate pain during in-office procedures. Notably, techniques including pharmacological analgesics, hand holding, heating pads, entertainment/virtual reality, and distraction have shown significant efficacy. Existing studies explore risk factors influencing pain intensity during prostate biopsy and effective pain management strategies. This review consolidates available information to guide clinicians in enhancing patient comfort and thus, encourage surveillance adherence.","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Transurethral BPH Surgeries in Management of Urinary Symptoms in Prostate Cancer Patients, Narrative Review. 经尿道前列腺增生手术在治疗前列腺癌患者尿路症状中的作用，叙述性综述。

IF 2.5 2区医学

Current Urology Reports Pub Date : 2024-10-01 DOI: 10.1007/s11934-024-01229-1

Mohamed Elsaqa, Marawan M El Tayeb

{"title":"The Role of Transurethral BPH Surgeries in Management of Urinary Symptoms in Prostate Cancer Patients, Narrative Review.","authors":"Mohamed Elsaqa, Marawan M El Tayeb","doi":"10.1007/s11934-024-01229-1","DOIUrl":"10.1007/s11934-024-01229-1","url":null,"abstract":"Purpose of review: Prostate cancer and benign prostate hyperplasia (BPH) are two ubiquitous pathologies that may coexist. A significant percentage of patients with different stages of prostate cancer suffer lower urinary tract symptoms (LUTS) due to associated BPH. We aimed to review the literature regarding the role of transurethral surgeries in the management of prostate cancer patients and the different available management options.Recent findings: The evidence in literature for the use of BPH surgeries in prostate cancer patients is based mainly on low-quality retrospective studies. In patients on active surveillance, BPH surgeries are beneficial in relieving LUTS without oncological risk and can eliminate the contribution of adenoma to PSA level. In patients with advanced prostate cancer, palliative BPH surgery can relieve LUTS and urinary retention with unclear oncological impact; however some reports depict that the need for BPH surgery in advanced prostate cancer is associated with poorer prognosis. In patients receiving radiotherapy, various studies showed that transurethral resection of prostate (TURP) is associated with increased radiotoxicity despite some recent reports encouraging the use of Holmium Laser Enucleation of the Prostate (HoLEP) to improve urinary symptom scores before radiotherapy. The most commonly reported techniques utilized are TURP, photoselective vaporization of prostate (PVP) and HoLEP. The use of BPH surgery is justified for relieving LUTS in selected prostate cancer patients on active surveillance or in advanced stages, however the use in the pre-radiotherapy settings remains controversial. Future prospective and randomized controlled trials are required for validating the benefits and assessing potential hazards.","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11445351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genomics in active surveillance and post-prostatectomy patients: A review of when and how to use effectively. 主动监测和前列腺切除术后患者的基因组学：回顾何时以及如何有效使用。

IF 2.5 2区医学

Current Urology Reports Pub Date : 2024-10-01 Epub Date: 2024-06-13 DOI: 10.1007/s11934-024-01219-3

Adedayo Adetunji, Nikit Venishetty, Nita Gombakomba, Karl-Ray Jeune, Matthew Smith, Andrew Winer

{"title":"Genomics in active surveillance and post-prostatectomy patients: A review of when and how to use effectively.","authors":"Adedayo Adetunji, Nikit Venishetty, Nita Gombakomba, Karl-Ray Jeune, Matthew Smith, Andrew Winer","doi":"10.1007/s11934-024-01219-3","DOIUrl":"10.1007/s11934-024-01219-3","url":null,"abstract":"Purpose of review: Prostate cancer (PCa) represents a significant health burden globally, ranking as the most diagnosed cancer among men and a leading cause of cancer-related mortality. Conventional treatment methods such as radiation therapy or radical prostatectomy have significant side effects which often impact quality of life. As our understanding of the natural history and progression of PCa has evolved, so has the evolution of management options.Recent findings: Active surveillance (AS) has become an increasingly favored approach to the management of very low, low, and properly selected favorable intermediate risk PCa. AS permits ongoing observation and postpones intervention until definitive treatment is required. There are, however, challenges with selecting patients for AS, which further emphasizes the need for more precise tools to better risk stratify patients and choose candidates more accurately. Tissue-based biomarkers, such as ProMark, Prolaris, GPS (formerly Oncotype DX), and Decipher, are valuable because they improve the accuracy of patient selection for AS and offer important information on the prognosis and severity of disease. By enabling patients to be categorized according to their risk profiles, these biomarkers help physicians and patients make better informed treatment choices and lower the possibility of overtreatment. Even with their potential, further standardization and validation of these biomarkers is required to guarantee their broad clinical utility. Active surveillance has emerged as a preferred strategy for managing low-risk prostate cancer, and tissue-based biomarkers play a crucial role in refining patient selection and risk stratification. Standardization and validation of these biomarkers are essential to ensure their widespread clinical use and optimize patient outcomes.","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141310317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0